{'fraction_non_alphanumeric': 0.028688524590163935, 'fraction_numerical': 0.0, 'mean_word_length': 5.980952380952381, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The IUSM‐Purdue Alzheimer’s Disease Drug Discovery Center: A member of the NIH‐funded TREAT‐AD consortium

The Target Enablement to Advance Therapeutics for Alzheimer’s Disease (TREAT‐AD) Consortium is a newly formed NIA initiative designed to accelerate the discovery of new medicines for Alzheimer’s Disease. It is comprised of two drug discovery centers: OPEN‐AD and the Indiana University School of Medicine‐Purdue University Alzheimer’s Disease Drug Discovery Center (IUSM‐Purdue ADDD Center). The strategic goal of the consortium is to integrate sophisticated capability for early drug discovery and contribute to a broad study of emerging Alzheimer’s Disease target hypotheses to create new classes of potential therapeutics.